Abeona Therapeutics Q2 net loss $16.7M; on track for EB-101 BLA submission in Q3 2023

ABEONA THERAPEUTICS INC.

2023-Q2 EPS reported $1.48 revenue$3,500,000

Net loss $16.7M ($0.92/share) vs $7.9M ($1.36/share) in Q2 2022; revenue $3.5M from license.
Cash $37.1M at June 30; $25M July offering extends runway into Q4 2024.
BLA submission for EB-101 in RDEB on track for Q3 2023; pre-BLA briefing submitted to FDA.
Completed Process Performance Qualification runs for commercial production of EB-101.
Additional Phase 3 VIITAL efficacy/safety data presented at ISID and SPD meetings.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ABEONA THERAPEUTICS INC. reported second quarter of 2023 results: revenue $3.5 million, net income $16.7 million, EPS $0.92 loss per common share.

Period: second quarter of 2023
Revenue: $3.5 million
Net income: $16.7 million
EPS: $0.92 loss per common share
Result: reported results

Exact text from the filing

direct offering in July 2023, are sufficient resources to fund operations into the fourth quarter of 2024. License and other revenues in the second quarter of 2023 were $3.5 million, compared to $1.0 million in the second quarter of 2022. Research and development expenses for the three months ended June 30, 2023 were $8.5 million, compared to $6.7 million

View on SEC.gov

52 earnings releases filed in the last 30 days. Browse all earnings releases →

ABEONA THERAPEUTICS INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-027107

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.